OncoSec Medical Inc (NASDAQ: ONCS) is having a great day in the market today, and for good reason. The comapny announced collaboration news, exciting investors and sending the stock on a run for the top. Today, we’ll talk about:
- The collaboration news;
- what we’re seeing from ONCS stock as a result; and
- what we’ll be watching for ahead.
ONCS Stock Gains On Collaboration News
As mentioned above, OncoSec Medical is having a great day in the market today after announcing that it has entered into a new collaboration. The news came via press release early this morning.
In the release, ONCS said that it entered into a collaborative research agreement with Duke University School of Medicine. Under the terms of the agreement, the two entities will evaluate the use of the company’s proprietary TAVOPLUS in combination or sequence with a HER2-plasmid vaccine adminstered with OncoSec’s novel intratumeral delivery system.
In the release, the company said that research will be led by Herbert Kim Lyerly, M.D., George Bath Geller Professor, Professor of Immunology, Surgery and Pathology at Duke University School of Medicine.
As part of the agreement, ONCS will provide its proprietary TAVO and its new electroporation generator, APOLLO, using lower voltage and a longer pulse width which greatly increases DNA-plasmid cellular transfection rates.
In a statement, Dr. Lyerly, had the following to offer:
We are eager to expand our immunotherapy research in breast cancer through this collaboration with OncoSec. We have previously demonstrated, in a variety of breast cancer models, that local delivery of IL-12 stimulates an anti-breast cancer immune response with applicability beyond end-stage cancer. This delivery system has the potential to be a foundational therapeutic in the treatment of early-stage disease.
The translational work with TAVOPLUS has been very encouraging and we are excited to explore the potential of OncoSec’s IL-12 plasmid delivery technology to enhance immune responses targeting HER2+ tumors and to elicit superior T-cell and B-cell responses to HER2 in a variety of preclinical breast cancer models.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to OncoSec, the news proved to be incredibly positive.
After all, this research collaboration has the potential to lead to a marketable treatment option. Of course, that would drive revenue through the door.
So, it’s not surprising to see that excited investors are pushing the stock up in the market this morning. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:23), ONCS is trading at $0.74 per share after a gain of $0.14 per share or 23.33% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ONCS. In particular, we’re interested in following the story surrounding the company’s work with Duke as well as their continued work to develope their impressive pipeline. Nonetheless, we’ll keep an eye on the story and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!